Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PBYI

PBYI - Puma Biotechnology Inc Stock Price, Fair Value and News

$6.33-0.24 (-3.65%)
Market Closed

52/100

PBYI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

52/100

PBYI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.48

Target 3M

$6.43

Target 6M

$6.45

PBYI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PBYI Price Action

Last 7 days

-8.1%

Last 30 days

3.9%

Last 90 days

15.9%

Trailing 12 Months

108.9%

PBYI RSI Chart

PBYI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PBYI Valuation

Market Cap

319.0M

Price/Earnings (Trailing)

8.63

Price/Sales (Trailing)

1.5

EV/EBITDA

5.4

Price/Free Cashflow

7.44

PBYI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.48

Target 3M

$6.43

Target 6M

$6.45

PBYI Fundamentals

PBYI Revenue

Revenue (TTM)

212.0M

Rev. Growth (Yr)

-32.36%

Rev. Growth (Qtr)

3.89%

PBYI Earnings

Earnings (TTM)

37.0M

Earnings Growth (Yr)

-56.47%

Earnings Growth (Qtr)

51.05%

PBYI Profitability

Operating Margin

70.56%

EBT Margin

14.58%

Return on Equity

32.08%

Return on Assets

18.23%

Free Cashflow Yield

13.44%

PBYI Investor Care

Shares Dilution (1Y)

2.66%

Diluted EPS (TTM)

0.75

PBYI Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025232.7M238.1M212.0M0
2024226.6M219.1M243.6M230.5M
2023235.1M230.1M229.1M235.6M
2022200.7M206.9M217.7M228.0M
2021272.1M254.9M250.4M253.2M
2020224.4M241.1M235.5M225.1M
2019283.5M286.7M280.4M272.3M
201886.3M145.0M201.5M251.0M
201700027.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Puma Biotechnology Inc

PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
 CEO
 WEBSITEpumabiotechnology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES192

Puma Biotechnology Inc Frequently Asked Questions

PBYI is the stock ticker symbol of Puma Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Puma Biotechnology Inc is 318.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PBYI's fair value in chart for subscribers.

The fair value guage provides a quick view whether PBYI is over valued or under valued. Whether Puma Biotechnology Inc is cheap or expensive depends on the assumptions which impact Puma Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PBYI.

As of Wed Jan 28 2026, PBYI's PE ratio (Price to Earnings) is 8.63 and Price to Sales (PS) ratio is 1.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBYI PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Puma Biotechnology Inc has provided -0.172 (multiply by 100 for percentage) rate of return.